Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (271-280 of 373) with videos related to

Pageof 38
Sort By:
The British Journal of Dermatology|October 23, 2009
Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trialA B Kimball, J R Kaczvinsky, J Li, et al.
Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|September 29, 2025
The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trialJames M Kilgour, Hal Landy, Alexa B Kimball, et al.
American Journal of Clinical Dermatology|June 28, 2023
Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort StudyAmit Garg, Yvonne Geissbühler, Emma Houchen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatmentJoel M Gelfand, Alexa B Kimball, Eliot N Mostow, et al.
Dermatology and Therapy|December 5, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK AnalysisApril W Armstrong, Richard B Warren, Howard Sofen, et al.
The Journal of Organic Chemistry|April 13, 2004
The isoindazole nucleus as a donor in fullerene-based dyads. Evidence for electron transferJuan L Delgado, Pilar de la Cruz, Vicente López-Arza, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Pageof 38

Showing results (271-280 of 373) with videos related to

Sort By:
Pageof 38
The British Journal of Dermatology|October 23, 2009
Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trialA B Kimball, J R Kaczvinsky, J Li, et al.
Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|September 29, 2025
The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trialJames M Kilgour, Hal Landy, Alexa B Kimball, et al.
American Journal of Clinical Dermatology|June 28, 2023
Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort StudyAmit Garg, Yvonne Geissbühler, Emma Houchen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatmentJoel M Gelfand, Alexa B Kimball, Eliot N Mostow, et al.
Dermatology and Therapy|December 5, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK AnalysisApril W Armstrong, Richard B Warren, Howard Sofen, et al.
The Journal of Organic Chemistry|April 13, 2004
The isoindazole nucleus as a donor in fullerene-based dyads. Evidence for electron transferJuan L Delgado, Pilar de la Cruz, Vicente López-Arza, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Pageof 38